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Objective: To study the potential efficacy and tolerability of a natural multiherbal formula 
(Immumax) containing Echinacea extract 120 mg, garlic powder 100 mg, Nigella sativa oil 
200 mg, and Panax ginseng extract 50 mg plus vitamin C 50 mg and elemental zinc 7.5 mg in 
the treatment of patients suffering from the common cold.
Design and setting: The study was conducted in a prospective, double-blind, randomized, 
controlled study design in an outpatient setting.
Patients and methods: Sixty-two eligible patients with symptoms of the common cold were 
randomized to either Immumax or placebo treatment groups for the duration of their symptoms 
or a maximum of 14 days. Resolution rates were estimated using Kaplan–Meier analysis, and 
resolution profiles were compared between groups using the log-rank test. The mean percentage 
change in total symptom severity scores at days 4 and 8 from baseline were compared between 
the two groups by one-way analysis of variance (ANOVA).
Results: The median (interquartile range) time to resolution of all symptoms was 8 (5–9) days 
in the placebo group and 4 (3–6) days in the Immumax group. The results of the log-rank test 
indicate that symptoms resolved significantly faster in the Immumax group than in the placebo 
group (P , 0.001). The mean percentage reduction in total symptom severity scores from 
baseline at days 4 and 8 was significantly greater in the Immumax group than in the placebo 
group by one-way ANOVA (P , 0.01).
Conclusion: We can conclude from our study that Immumax is helpful in reducing the duration 
and severity of common cold symptoms.
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Introduction
The common cold is one of the most prevalent acute illnesses worldwide. It is 
implicated in about 40% of time lost from employment and 30% of time lost from 
  education.1 Most adults contract two to four colds per year, whereas children can have 
as many as 10 colds per year, producing substantial expenditure for physician office 
visits and over-the-counter cold and cough remedies.1,2 The infection is self-limiting. 
It usually resolves within 7 days, but many colds persist for up to 3 weeks and are due 
to various viruses. Although it is known that rhinovirus infections cause 10%–40% of 
colds,1 with coronavirus, parainfluenza virus, adenovirus, echovirus, and coxsackie 
virus accounting for the remainder of cases,3,4 these viruses produce clinically indis-
tinguishable disease,5,6 making specific viral diagnosis difficult. Available remedies 
act only to alleviate the cold symptoms (sneezing, nasal stuffiness and discharge, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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sore or scratchy throat, cough, hoarseness, headache, fever, 
and myalgia) and have no true therapeutic benefit toward 
eliminating the viral challenge.2,7,8
Echinacea, a member of the Compositae family, is a herb 
widely used to treat and prevent common illnesses,9 as it has 
been shown to have immunostimulatory properties.10 Three 
out of the nine species in this family are of medicinal   interest 
(Echinacea angustifolia, E. pallida, and E. purpurea). They 
are commonly used to treat viral upper respiratory tract 
infections.11 Echinacea causes an increase in numbers of 
circulating white blood cells, activation of phagocytosis by 
human granulocytes, and elevation of body temperature,12 
resulting primarily from the aerial portion of E. purpurea13 
and the root portion of E. pallida.13 Previous research sug-
gests that Echinacea may be most effective at reducing the 
severity and duration of the common cold when taken early 
in the illness14,15 but has little to no preventive benefit.16 
A review of five randomized, clinical trials investigating the 
immunomodulatory activity of Echinacea concluded that 
Echinacea may be an efficacious immune stimulator.17
Garlic (Allium sativum) is one of the oldest medicinal 
plants used by different cultures. The oldest reports of health-
promoting properties of garlic date back to the16th century 
BC, when in the Ebers Papyrus from Egypt over 20 ailments 
were purported to be efficiently cured by garlic.18 Garlic 
stimulates the immune system and acts as a natural antibiotic 
not harmful to friendly bacterial flora. Many laboratory stud-
ies have confirmed the antibacterial, antifungal, antivirus, 
immunostimulating, and antioxidant properties of garlic.19–23 In 
1990, the US National Cancer Institute initiated the Designer 
Food Program to determine which foods played an important 
role in cancer prevention; they concluded that garlic may be 
the most potent food with cancer-preventive properties.24
Nigella sativa is the black seed referred to by the prophet 
Mohammed as having healing powers. It is also identified as 
the curative black cumin in the Holy Bible and is described 
as the Melanthion of Hippocrates and Discroides and as the 
Gith of Pliny.25
The effect of N. sativa on immune responses was evalu-
ated in human volunteers. The results showed that black seed 
enhanced by 55% the ratio between helper T cells (CD4) and 
the suppressor T cells (CD8), and a 30% average enhance-
ment of the natural killer (NK) cell activity.26 N. sativa has 
also established efficacy against several species of pathogenic 
bacteria (Staphylococcus aureus, Pseudomonas aeruginosa) 
and pathogenic yeast (Candida albicans).27
Extracts of American ginseng (Panax quinquefolium) 
have been shown to have immunomodulatory effects.28–34 
These extracts have been shown to enhance immune 
responses such as immunoglobulin production by lympho-
cytes and natural immune responses by peritoneal exudate 
macrophages.28 They have also been found to enhance anti-
complementary and reticuloendothelial system activities,29 
enhance macrophage Fc receptor expression,30 increase 
the phagocytosis index along with phagocytosis fraction,31 
and induce messenger RNA expression of interleukin-2 
(IL-2), interferon-gamma (IFN-γ), interleukin-1, and 
granulocyte-macrophage colony-stimulating factor as well 
as lymphokine-activated killer cells and CD8+ cells.32 
In addition, these extracts appear to stimulate cell-mediated 
immune response and NK cell cytotoxicity,33 as well as to 
have cytotoxic effects on a wide range of tumor cell lines 
without major histocompatibility complex restriction.34 
Ginseng extract was found to effectively prevent acute 
respiratory illness due to influenza and respiratory syncytial 
virus by 89% in a clinical trial involving elderly people liv-
ing in institutions.35
Vitamin C, (ascorbic acid), is a water-soluble vitamin 
found in fruit and vegetables, particularly citrus fruit. It 
is necessary for iron absorption, wound healing, and col-
lagen formation.36 Vitamin C is also recognized as being 
important to the successful production of neurotransmitters 
and improvement of glucose metabolism; its deficiency 
results in the neurological disease of scurvy.37 Vitamin C’s 
association with immune strengthening is derived from 
its ability to enhance the function of the immune system, 
including antimicrobial and NK cell activities, macrophages, 
lymphocyte proliferation, chemotaxis, and delayed-type 
hypersensitivity.38
Zinc salts have been found to inhibit rhinovirus 
  replication in vitro at concentrations of ,0.1 mmol/L,39 
possibly by interfering with rhinovirus protein cleavage.38 
Alternatively, it has been suggested that zinc salts may 
protect plasma membranes against lysis by cytotoxic agents 
such as microbial toxins and complement.40 The proposed 
protective mechanism is either via immunomodulation41,42 
or via the binding of zinc ions to rhinovirus surface can-
yons, thus inhibiting viral interactions with intercellular 
adhesion molecule-1 (ICAM-1), the site of rhinovirus bind-
ing to cells.43 Because ICAM-1 is also the binding site for 
leukocyte function associated antigen-1 (LFA-1), the block 
of LFA-1/ICAM-1 binding has been postulated to possibly 
suppress inflammation.43 Several randomized, controlled 
clinical studies showed a beneficial effect of using zinc for 
treating the common cold, particularly when zinc is started 
within the first 24 hours of onset of symptoms.44–47International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Immumax, a product of Beovita-Safe Pharma, an Egyp-
tian–German pharmaceutical company, is a combination of 
natural herbal extracts, including Echinacea extract 120 mg, 
garlic powder 100 mg, Nigella sativa oil 200 mg, and Panax 
ginseng extract 50 mg plus vitamin C 50 mg and elemental 
zinc 7.5 mg.
Objective
The multiple immunomodulatory activities at different lev-
els and the proven in vitro antiviral activities have encour-
aged us to study the potential efficacy and tolerability of this 
multi-ingredient formula in the treatment of human patients 
suffering from the common cold.
Design and setting
The study was conducted in a prospective, double-blind, 
randomized, controlled manner in an outpatient setting.
Patients and methods
To detect a difference of 3 days between the mean duration 
of symptoms in the two treatment groups with a standard 
deviation of 4 days, given a two-sided P value of 0.05 and 
an approximate power of 80%, we calculated the sample size 
for each group to be 28 patients.
Sixty-two consecutive patients presenting to two outpa-
tient clinics in Alexandria, Egypt, suffering from common 
cold symptoms and meeting the eligibility criteria (stated in 
Inclusion criteria) in the period between 5 September 2009 and 
5 March 2010 were recruited to the study. The local research 
ethical committee approved the study protocol, and all partici-
pants signed informed consents at the time of enrollment.
Inclusion criteria
Patients were included if they had had cold symptoms for 
36 hours or less. Patients must have had at least two of the 
following 10 symptoms: cough, headache, hoarseness, mus-
cle aches, nasal discharge, nasal congestion, scratchy throat, 
sore throat, sneezing, or an oral temperature .37.7°C.
exclusion criteria
Patients were excluded if they were pregnant; had a known 
immune deficiency, cancer, severe liver/renal dysfunction, 
or critical illness; or had had symptoms of the common cold 
for more than 36 hours.
Interventions
Immumax capsules and identical placebo capsules contain-
ing beeswax were packed and coded by a research assistant 
blinded to the study participants. Patients fulfilling the 
inclusion/exclusion criteria were randomly divided into two 
treatment groups: an experimental group who started treat-
ment with Immumax at a dose of one capsule twice daily 
until recovery of symptoms or a maximum of 14 days, and 
a control group who took one placebo capsule twice daily 
with the same regimen. Randomization was done using a 
software-generated block randomization technique, and 
patients and investigators were blinded to the allocated drug. 
The randomization list and the drug codes were locked in 
sealed envelopes until the end of the follow-up period, final 
assessment, and statistical analysis. Each patient was given 
a similar pack of 30 capsules and was asked to swallow one 
capsule twice daily for as long as he/she had cold symptoms. 
The first capsule was administered just after enrollment at the 
clinic to assess initial tolerability. Participants were asked 
to take no other cold preparations during the study period 
apart from acetaminophen for symptomatic relief of pain or 
fever on an as-needed basis. Oral thermometers were given 
to the patients at the time of enrollment. All patients were 
asked to revisit at day 1 after the start of treatment and within 
1 day of noting that their cold symptoms had resolved. At 
this visit, they returned unused capsules so that adherence 
to the protocol could be checked through capsule counts and 
the treating physician could confirm that cold symptoms 
had resolved.
Patients were asked to complete a daily record docu-
menting the severity of symptoms and the medications 
taken throughout the duration of their cold or for as long 
as 14 days.
Every day, patients graded each symptom as 0 for none, 
1 for mild, 2 for moderate, or 3 for severe. Total symptom 
scores were calculated by summing the scores of all symp-
toms for each patient each day. Cold resolution was defined 
as resolution of all symptoms (a total symptom score of 0) 
or resolution of all but one mild symptom (a total symptom 
score of 1).
Statistical analysis
The time to cold resolution was calculated as the number of 
days from study entry and summarized as median (interquartile 
range [IQR]) for each treatment group. Resolution rates were 
estimated using the Kaplan–Meier method, and resolution 
profiles were compared between groups using the log-rank 
test. The mean percentage change in total symptom severity 
scores at days 4 and 8 from baseline were compared between 
the two groups by one-way analysis of variance (ANOVA). 
Chi-square test (or Fisher’s exact test) was used to analyze International Journal of General Medicine 2011:4
Assessed for eligibility (n = 75)
Total excluded (n = 13) 
 Not meeting inclusion criteria
(n = 9)
Refused to participate
(n =  4)  
Analyzed (n = 30) 
Excluded from analysis
(n = 0) 
Lost to follow-up (n = 2)
(Did not show up)
Discontinued intervention
(n = 0) 
Allocated to Immumax (n = 31) 
Received allocated intervention
(n = 30) 
Did not receive allocated
intervention (n = 1) intolerable 
Lost to follow-up (n = 1)
(Did not show up) 
Discontinued intervention
(n = 2) 
(Needed antibiotic
therapy for complications) 
Allocated to placebo (n = 31) 
Received allocated
intervention (n = 31) 
Did not receive allocated
intervention (n = 0) 
Analyzed (n = 31) 
Excluded from analysis
(n = 0) 
Allocation
Analysis 
Follow-up 
Enrollment 
62 randomized
Figure 1 Flowchart of patients.
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associations between the side effects and assigned groups. 
Patients were considered adherent if they took an average of 
two capsules per day for the first 4 days of the study (eight 
capsules) and if they took no antibiotic agents.
Results
Seventy-five patients presenting with common cold symp-
toms were assessed for eligibility criteria. Nine of them 
were excluded, as they did not fulfill the eligibility criteria, 
whereas another four refused to sign the informed consent. 
Sixty-two patients were randomized to two equal groups: 
31 patients were assigned to the Immumax group, and the 
remaining 31 were assigned to the placebo group. One 
patient in the Immumax group withdrew from the study 
on the first day because he could not tolerate the capsules 
(see Figure 1). All other patients, as directly observed by International Journal of General Medicine 2011:4
Table 1 Baseline characteristics of the 62 randomized patients
Variable Placebo Immumax
number randomized 31 31
Age mean (SD) 38.6 (9.4) 37.9 (7.5)
Sex (male/female)  19/12 17/14
Smokers 5 4
history of allergy 12 14
Baseline symptom scores:
  Mean (±SD) 8.6 (±3.1) 8.1 (±3.6)
  Median 8 8
Abbreviation: SD, standard deviation.
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Figure 2 Kaplan–Meier curve for the duration of colds in 61 patients. The blue line (lower curve) represents Immumax, and the green line represents the placebo group.
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the study nurse, indicated that they had good tolerance of 
the first dose.
Baseline characteristics of the two groups are given in 
Table 1. The incidence and severity of individual symptoms 
at baseline, as well as other demographic characteristics, 
were almost similar in the two groups.
Seven patients (five in the placebo group and two in the 
Immumax group) had colds that were not reported to resolve 
during the follow-up period of the study (censored). Two of 
these patients (both were placebo recipients) completed the 
14 days of the study with remaining symptoms. Another two 
patients of the placebo group reported that their conditions 
had worsened and needed to be treated with antibiotics for 
lower respiratory tract bacterial infection. The remaining 
three of the seven censored patients were lost to follow-up, 
two from the Immumax group and one from the placebo-
treated group.
We used Kaplan–Meier survival analysis to esti-
mate the percentage of patients whose colds resolved 
(a total symptom score of #1) on each day of the study 
(Figure 2).
The median (IQR) time to resolution of all symptoms 
was 8 (5–9) days in the placebo group and 4 (3–6) days 
in the Immumax group. The results of the log-rank test 
indicate that symptoms resolved significantly faster in the 
Immumax group than in the placebo group (P , 0.001). 
There was no significant difference in compliance between 
groups during the first 4 days of therapy (P , 0.05). The 
mean percentage reduction in total symptom severity scores 
from baseline at days 4 and 8 was significantly greater in 
the Immumax group than in the placebo group by one-way 
ANOVA (Table 2).
At the end of the study, eight (39%) of the placebo 
recipients and 18 (60%) of the Immumax recipients reported 
that the study medication had helped improve their cold 
symptoms (P = 0.01). The frequency of reported adverse 
effects, including nausea, vomiting, abdominal pain, diar-
rhea, fatigue, and dizziness, did not differ significantly 
between the two groups.
Discussion
To our knowledge, this is the first study to test the effect of 
this multiherbal preparation with vitamin C and zinc (already 
consumed as a dietary supplement) on the duration and 
  severity of common cold symptoms. As we have indicated 
in our introduction, a plethora of data in the literature, either 
basic or clinical studies, addresses the immunostimulatory 
and antiviral activities for each of the components.10–47 We 
opted to conduct this simple pilot study as a pragmatic International Journal of General Medicine 2011:4
Table 2 comparison of mean percentage reduction in total symptom severity scores
Variable Group N Mean 95% CI F P
Lower  
bound
Upper  
bound
Percentage reduction at day 4 Immumax 30 56.79 52.26 61.32 8.45 0.005
Placebo 31 47.99 43.77 52.21
Percentage reduction at day 8 Immumax 30 95.07 92.96 97.17 15.83 0.0002
Placebo 31 86.40 82.52 90.27
Abbreviation: CI, confidence interval.
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hypothesis rather than as a confirmatory or explanatory 
study.
In our opinion, alternative medicine is in need of much 
translational research and clinical trials on human subjects 
to be performed and published in scientific literature, espe-
cially for those products that are already being consumed as 
over-the-counter dietary supplements. The authors admit that 
there are many limitations in this study, including its small 
size, the short follow-up period, the dependence mainly on 
symptoms, and subjective scoring as outcome measures 
without correlating findings with more objective laboratory 
data. These limitations can be explained by the perception 
that studies on alternative medicine, due to lack of patent 
protections, unlike those on patented new chemical entities 
funded from the pharmaceutical industry, usually suffer 
financial and logistic constraints.
Conclusion
We can conclude from our study that Immumax is help-
ful in reducing the duration and severity of common cold 
symptoms. More confirmatory and explanatory randomized 
studies are needed to confirm this.
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and placebo.
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